Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) PT at $40.17


Share on StockTwits

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have received a consensus recommendation of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $37.57.

Several research firms have recently issued reports on MIRM. Raymond James increased their target price on shares of Mirum Pharmaceuticals from $48.00 to $52.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 13th. SVB Leerink began coverage on shares of Mirum Pharmaceuticals in a report on Monday, February 8th. They issued an “outperform” rating and a $38.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Mirum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a report on Tuesday.

NASDAQ:MIRM traded down $0.57 during mid-day trading on Tuesday, hitting $18.87. The company’s stock had a trading volume of 4,289 shares, compared to its average volume of 148,012. Mirum Pharmaceuticals has a 1 year low of $9.14 and a 1 year high of $27.43. The stock has a market cap of $485.28 million, a price-to-earnings ratio of -5.65 and a beta of 2.44. The business’s fifty day moving average is $19.43 and its two-hundred day moving average is $20.31.

In other news, CEO Christopher Peetz bought 5,000 shares of the stock in a transaction dated Wednesday, December 23rd. The shares were acquired at an average price of $18.70 per share, with a total value of $93,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,371 shares in the company, valued at $25,637.70. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Ian Clements bought 2,470 shares of the stock in a transaction dated Wednesday, December 23rd. The stock was purchased at an average cost of $18.61 per share, for a total transaction of $45,966.70. Following the acquisition, the chief financial officer now owns 6,279 shares of the company’s stock, valued at $116,852.19. The disclosure for this purchase can be found here. Corporate insiders own 45.50% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in MIRM. Charles Schwab Investment Management Inc. boosted its holdings in Mirum Pharmaceuticals by 38.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 15,333 shares of the company’s stock worth $299,000 after buying an additional 4,255 shares in the last quarter. Nuveen Asset Management LLC purchased a new stake in Mirum Pharmaceuticals during the second quarter worth about $202,000. Lindbrook Capital LLC boosted its holdings in Mirum Pharmaceuticals by 200.0% during the third quarter. Lindbrook Capital LLC now owns 1,500 shares of the company’s stock worth $29,000 after buying an additional 1,000 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Mirum Pharmaceuticals by 73.9% during the third quarter. New York State Common Retirement Fund now owns 5,412 shares of the company’s stock worth $104,000 after buying an additional 2,300 shares in the last quarter. Finally, State Street Corp boosted its holdings in Mirum Pharmaceuticals by 7.5% during the third quarter. State Street Corp now owns 102,803 shares of the company’s stock worth $1,981,000 after buying an additional 7,148 shares in the last quarter. 72.90% of the stock is currently owned by hedge funds and other institutional investors.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.

See Also: Analyst Ratings

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.